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Abstract—Microarray-based global gene expression profiling, 
with the use of sophisticated statistical algorithms is providing new 
insights into the pathogenesis of autoimmune diseases. We have 
applied a novel statistical technique for gene selection based on ma-
chine learning approaches to analyze microarray expression data 
gathered from patients with systemic lupus erythematosus (SLE) 
and primary antiphospholipid syndrome (PAPS), two autoimmune 
diseases of unknown genetic origin that share many common fea-
tures. The methodology included a combination of three data dis-
cretization policies, a consensus gene selection method, and a mul-
tivariate correlation measurement. A set of 150 genes was found to 
discriminate SLE and PAPS patients from healthy individuals. Sta-
tistical validations demonstrate the relevance of this gene set from 
an univariate and multivariate perspective. Moreover, functional 
characterization of these genes identified an interferon-regulated 
gene signature, consistent with previous reports. It also revealed 
the existence of other regulatory pathways, including those regu-
lated by PTEN, TNF, and BCL-2, which are altered in SLE and 
PAPS. Remarkably, a significant number of these genes carry E2F 
binding motifs in their promoters, projecting a role for E2F in the 
regulation of autoimmunity. 
Index Terms—Antiphospholipid syndrome, DNA microarrays, 
gene profiling, machine learning, systemic lupus erythematosus. 
I. INTRODUCTION 
DNA MICROARRAY technology [1] offers the possibility to simultaneously analyze the expression of hundreds to 
thousands of genes [2]. This approach has been applied suc-
cessfully to better classify many cancers and to understand 
the molecular pathways involved in several pathologies [3]. 
Genome-wide gene expression profiles of autoimmune diseases, 
such as systemic lupus erythematosus, rheumatoid arthritis, or 
Sjogren's syndrome have also been obtained [4]. These stud-
ies have identified genes with a dysregulated expression in au-
toimmune diseases. Further application of microarray analyses 
should facilitate the identification of pathways that are common 
in autoimmunity, but more importantly, genes and pathways 
that uniquely define patients with a particular disease pheno-
type, which could be useful for the development of specific 
treatments [5]. 
Despite the demonstrated power of high-throughput gene ex-
pression profiling approaches, some important limitations have 
been noted. DNA microarray analyses are typically hypothesis-
driven, in the sense that the experiments are designed to address 
a scientific question [6], an approach that could lead to a biased 
interpretation of the results. Additionally, because microarrays 
are inherently noisy, they impact on data quality [7]. Moreover, 
present microarray studies usually include a very low number 
of samples under study. In this context, the reliability of a single 
data mining technique is no guarantee at all. Clear evidence of 
these effects is the differences found within the results of data 
analysis techniques for the same microarray data [8]. 
The discipline of machine learning, in combination with data 
mining techniques has been very useful in diverse fields of re-
search, including the bioinformatics discipline, to overcome the 
technology-intrinsic data noise and to obtain relevant knowledge 
out of a high volume of data [9]. An important feature of this 
method relies on the fact that no prior knowledge of the system 
under study is necessary to run the analysis, thus constituting a 
blind process for which the final results are only based on the 
characteristics of the raw data. Due to this blindness, a strict val-
idation of the results needs to be tackled: statistical relevance, 
laboratory qPCR validation, bibliographic revision, regulatory 
activity evaluation, and dysregulation of transcription factors, 
among others. 
We have now applied machine learning procedures to DNA 
microarray data derived from samples of patients suffering from 
systemic lupus erythematosus (SLE) and primary antiphospho-
lipid syndrome (PAPS), two autoimmune conditions with over-
lapping immunological features, in order to obtain an unbiased 
identification of genes that could be relevant to the pathogene-
sis of these diseases. We propose that the computational tools 
employed in this paper add robustness to the microarray-based 
identification of biomarkers. 
The paper is divided into four main sections. Section II 
presents the materials and methods used in this research giv-
ing as much technical information as possible for each tackled 
stage. The results and their validations are gathered and dis-
cussed in Section III. This section is divided into two sections 
(Section III-A and IITB), each of which focus on the statistical 
and the biological validation, respectively. Brief conclusions are 
Anally provided in Section IV. 
II. MATERIALS AND METHODS 
A. Study Participants 
After informed consent, patients and controls provided a pe-
ripheral blood sample, and peripheral blood mononuclear cell 
(PBMC) were isolated from whole blood by flcoll gradient pu-
rification (GE Helathcare Bio-Sciences, Piscataway, NJ, USA). 
All patients were Caucasian women, and had physician-verified 
SLE or PAPS. Data on age, clinical characteristics, disease ac-
tivity, and current medication are summarized in the online 
supplementary content.l Disease activity in SLE patients was 
determined using systemic lupus erythematosus disease activity 
index (SLEDAI) score [10]. 
B. Sample Processing and Chip Hybridization 
For microarray experiments, four patients with SLE, two pa-
tients with primary APS, and five healthy individuals were used 
(see supplementary content). RNA was extracted from PBMC 
using triZOL (Invitrogen, Carlsbad, CA, USA) followed by 
RNeasy cleanup (Qiagen, Hilden, Germany). The isolated RNA 
was amplified and labeled as described in the GeneChip Expres-
sion Analysis Technical Manual (Affymetrix, CA, USA), and 
subsequently hybridized to HG-U133A Genechip microarrays 
(Affymetrix, CA, USA) and scanned according to the manufac-
turer's recommendations. The labeling, hybridization and scan-
ning procedures were carried out in Progenika (Derio, Spain). 
C. Data Acquisition and Preprocessing 
After scanning the arrays, Affymetrix microarray suite 
(MAS) 5.0 software was used for the compilation and initial 
analysis of the raw datasets. Four different quality values were 
measured in order to evaluate the reliability of the microarrays 
that were used in the experiment: spike control BioB, house-
keeping control GAPDH, P-call percentage, and array outlier 
percentage. Only the arrays that complied with the reliability 
criteria [11] were considered for further analysis. 
Affymetrix is a one-channel technology [1] that only includes 
one sample on each microarray. To study the intensity change 
shown by each probe between test and reference samples, com-
parisons were made between the reference and the test microar-
ray. On the basis of these comparisons, a second filter level 
was constituted: all probes showing an absent detection value 
in both microarrays were discarded from the analysis. Microar-
ray internal control sequences were also removed, and the final 
'Supplementary data and results for this study is available at: http://www. 
sc.ehu.es/ccwbayes/members/ruben/sle/ 
amount of probes under study was set at 8,808. The known 
logRatio between the two channel values was computed for 
each of the 8,808 probes, producing a total of 40 instances or 
comparisons (healthy versus healthy; SLE versus healthy; PAPS 
versus healthy). 
D. Relevant Gene List Identification 
From the statistics and data mining fields, the expression level 
of each gene is represented as a random variable of a probabilis-
tic process. A great number of machine learning methods are 
designed to deal only with discrete data, so, it becomes neces-
sary to translate the microarray data from continuous to discrete 
value domains. However, this process can bias the original data 
and degrade their original quality. In order to amplify the robust-
ness of the knowledge discovery process, and to overcome this 
possible bias, the use of a set of different discretization tech-
niques is suggested [12]. Thus, beginning with a microarray 
dataset discretized in different ways, we search for a consensus 
result with larger reliability and robustness than usual single-
discretization modeling. Due to the small sample sizes of gene 
expression databases, the community of researchers was rapidly 
aware about the potentialities of model consensus approaches 
to improve the robustness and stability of final discriminative 
rules [13], [14]. 
The consensus procedure that was put forward comprises the 
best techniques used in various data analysis fields. First, a set 
of discretization policies, namely: equal width [15], equal fre-
quency [16], and entropy [17]. Given a number of bins, b, equal 
width simply sorts the values a feature can take and divides the 
observed range into b equally sized intervals. Equal frequency 
divides the range into b bins that gather the same number of 
occurrences. As a usual criterion in this field [18], [19], our 
assumption is that a gene could be in three possible states, using 
the idea of over-, under- or baseline activity, so the number of 
bins is set to three. For its part, entropy discretization makes 
use of the phenotype distribution over the data, in conjunction 
with a minimum description length-based algorithm [20]. For 
each feature independently, this technique finds the appropriate 
cutoff points in such a way that the phenotype entropy within 
each resulting interval is minimum, while balancing this by in-
troducing as few cutoff points as possible. 
Second, a filter-like selection procedure to detect differen-
tially expressed genes among the studied phenotypes (correla-
tion feature selection) [21]. CFS belongs to the filter optimal 
subset selection techniques [22], it addresses two fundamental 
issues: avoid both redundancy and irrelevancy in the selected 
subset of genes. Making use of the uncertainty coefficient [21] 
and a classical forward greedy hill-climbing search strategy, 
CFS is able to identify the genes most correlated with the phe-
notype distribution keeping the redundancy among them mini-
mum. Bear in mind that there can be genes with a high phenotype 
correlation coefficient that are not included in the subset finally 
selected, so a third stage to amplify the relevant gene set is 
mandatory. 
And third, a statistical coexpression measure (a classical prob-
ability theory metric—mutual information—[23]). At this last 
selection 
Disci 
m PROTOTYPE 
GENES 
O ^rt5i^^ 
DÍSCN\ 
Feature , ^ 
SN I __• '_•( GN 
Co expression 
-V 
m PROTOTYPE 
GENES 
genei=1,...,rn< 
Co expression 
selection 
Fig. 1. Machine learning data flow to identify the relevant gene set: identifying the prototype genes and the genes mostly correlated with them. 
stage, we look for those possible genes that, having a biolog-
ically relevant role in the problem, have not enough statistical 
power to be considered as a separate prototype. Notice that, 
using the mutual information metric, and due to the fact that 
it has no sign consideration, the relationships found could be 
direct and inverse in the gene profiling. Thus, it can cover a key 
biological process: positive or negative transcription regulation. 
Formally, let the discrete datasets S I , . . . , S J V be the re-
sult of different discretization policies of the original O mi-
croarray dataset. N different feature subset selections are per-
formed on the basis of these S¿ discrete datasets, producing 
the following subsets of genes: G i , . . . , GN> The consensus 
gene subset Y (hereafter statistical prototypes) will be the 
intersection between all of them, that is r = f]i=1 Gi, with 
| T | = m < min¿=iv..5jv | G¿ |. In order to amplify the final 
output gene set, for each statistical prototype gene, its q most 
univariately correlated genes are also selected. Fig. 1 graphically 
exemplifies the whole information flow. 
The objective of the overall process was to enhance the ro-
bustness of the final solution. The use of different discretization 
procedures adds independence from a specific discretization 
task, and obtains a compact and biologically meaningful gene 
set T = p|¿=i Gi. The posterior enlargement of this statistical 
outcome can add information contained in each of the starting 
gene sets. The complete formulation of this novel combination 
of techniques and their comparison with other state-of-the-art 
approaches can be widely reviewed in [12]. 
E. Quantitative PCR 
DNA purified from six healthy donors, three SLE patients, 
and five PAPS patients (see supplementary content), all of them 
different from those used in microarray experiments, was re-
versed transcribed into cDNA. 
Quantitative TaqMan PCR analyses were performed for the 
following genes: H1F0, PPIA, GNLY, SSB, and SP100. In addi-
tion, qPCR of TBP was performed on all samples, which served 
as internal control. The primers and TaqMan probes for all the 
genes were obtained from Applied Biosystems (ABI, Foster 
City, CA, USA). The reactions were run by triplicate on an ABI 
7900HT fast real-time PCR system from Applied Biosystems at 
the Genomics Facility of the University of the Basque Country, 
using standard cycling conditions. Results were analyzed with 
the sequence detection system (SDS) Software v2.0 (Applied 
Biosystems) to obtain the Ct values for each sample. 
A DCt value was calculated reflecting the difference between 
the average Ct of the replicate samples obtained for the control 
gene (TBP) and the average Ct of the replicate samples obtained 
for the test gene to be validated. Using these DCt values as the 
raw expression value in the qPCR experiment, we first deter-
mined the median DCt for all the healthy control samples. Next, 
we calculated the difference between the DCt of each test sam-
ple and the DCt values of the healthy controls, thus obtaining a 
set of DDiff values for each phenotype and gene. 
III. RESULTS AND DISCUSSION 
SLE is an autoimmune disease characterized by the produc-
tion of autoantibodies with specificity for a wide range of self-
antigens, resulting in injury to various organ systems, including 
skin, joints, kidney, and central nervous system [24]. PAPS is a 
related autoimmune disease characterized by recurrent thrombo-
sis and miscarriages, associated with antiphospholipid autoanti-
bodies (aPL) directed against phospholipid-binding plasma pro-
teins as well as with other autoantibodies shared with SLE [25]. 
The antiphospholipid syndrome can manifest on its own, in 
the absence of lupus symptoms (primary APS, PAPS), or can 
develop secondarily in a subset of lupus patients, implying that 
some pathogenic pathways are common to both autoimmune 
diseases. To identify genes that discriminate SLE or PAPS 
patients from healthy controls, a novel set of computational 
tools was used based on a machine learning approach using the 
logRatio data from DNA microarrays, as indicated in Section II. 
A total of 150 probes (hereafter genes) out of an original set con-
taining more than 22,000 genes were detected as the relevant 
genes whose differential expression confidently discriminates 
among SLE patients, PAPS patients, and healthy controls. 
The complete list of relevant genes, including the Affymetrix 
probe ID, the gene symbol, their locus, and their relative gene 
expression in SLE or PAPS patients, and a short description 
are available online through the Supplementary content page. 
The significantly different expression profile exhibited by these 
genes in patients samples relative to samples of healthy con-
trols could contribute to the pathogenesis of the autoimmune 
conditions analyzed in this paper. 
The sample labeled as LB 10 corresponds to an SLE pa-
tient who developed secondary APS. We wished to determine 
whether the gene expression profile of this individual was more 
similar to primary APS or whether it maintained an SLE pat-
tern of gene expression. To this end, hierarchical clustering 
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TABLE I 
POSITIONS OF THE STATISTICAL PROTOTYPES OVER THE CONSENSUS 
RANKINGS FOR THE THREE DISCRETE SETS (EF, EW, AND ENTROPY) 
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Fig. 2. Clustering of the illness instances (SLE and PAPS). Branches colored 
in blue belong to SLE-class-labeled instances, while branches in red belong to 
PAPS instances. The expression profiles of each test sample were compared 
separately with the expression profiles of control samples, resulting in five 
comparisons for each SLE or PAPS sample. The five instances generated by 
sample LB 10 flawlessly behave as the rest of SLE instances, being all clustered 
in the same group. 
analysis was carried out considering the most common cluster-
ing parameters: Pearson correlation and average linkage. This 
analysis clearly showed that LB 10 is clustered with the rest 
of SLE patients and not with PAPS patients (see Fig. 2). Fur-
thermore, clustering of all SLE patients was very similar and 
homogeneous, implying that a secondary acquisition of an an-
tiphospholipid syndrome does not modify significantly the tran-
scriptional profile that characterizes SLE. 
Many of the genes identified in our study have not been previ-
ously implicated in SLE or PAPS, and represent new biomarkers 
of these diseases. Interestingly, a link with autoimmunity, and 
in particular to lupus, has already been established for a signifi-
cant number of the genes included in this group of dysregulated 
genes. Such is the case of the genes SSB, SP100, H1F0, all 
of which are lupus autoantigens [26]-[30] or TAP-1, a trans-
porter gene with polymorphisms showing genetic association 
with SLE [31] and [32], among others. 
A. Statistical Analysis 
From the 150 total genes returned by the machine learning 
stage, there were a total of eight statistical prototypes (CPSF1, 
SLC25A12, UQCRB, NADK, MICAL2, KIAA0776, PARL, 
and CECRl). It is mandatory to note that prototype genes are 
the result of a statistical process and their aim is to comprise 
the statistical axes of the problem. Although a direct biological 
translation could be made, it would have no biological link to 
the statistical and biological interpretations: the prototype genes 
could not have any special biological contribution in the domain 
of the diseases under study. 
The statistical analysis of the selected genes was performed in 
two ways: by measuring the relevance of the selected genes, and 
the estimated prediction accuracy in a supervised class predic-
Gene Ranking EF Ranking EW Ranking Entropy 
CPSF1 
SLC25A12 
UQCRB 
NADK 
MICAL2 
KIAA0776 
PARL 
CECRl 
22 
13 
33 
106 
11 
31 
1 
19 
93 
26 
33 
106 
14 
35 
3 
38 
46 
32 
51 
142 
20 
30 
12 
68 
tion procedure. For these two validations, the supervised target 
dataset was comprised of three different classes or phenotypes 
and 40 instances: 10 PAPS instances, 20 SLE instances, and 10 
control instances (see Section ll-C). A priori, the selected genes 
should be relevant to the problem, showing a high correlation 
degree with the phenotype distribution. 
Using the Elvira platform [33], and on the basis of the three 
discrete datasets, seven different univariate filter rankings [34] 
were calculated. Each of these seven metrics computes the corre-
lation coefficient of each gene with respect to the class variable. 
In order to obtain an average ranking for each dataset, each 
gene was weighted with a coefficient proportional to the rela-
tive positions shown in each ranking. The consensus rankings 
are accessible through the online supplementary content page, 
presenting a list of the 8,808 (924 in the case of entropy dis-
cretization) genes ordered by their correlation level with respect 
to the problem class label. 
Table I shows the positions of each statistical prototype in 
the consensus rankings of each discrete dataset. It is easy to 
check that the selected genes appear in the top positions of the 
rankings, with average positions of 29.5,43.5, and 50.1 for equal 
frequency (EF), equal width (EW), and entropy discretization, 
respectively. Such average positions significatively differ from 
the ones obtained if a random selection is made: 4004.5,4004.5, 
and 462.5, respectively. 
The second aspect of the statistical analysis comprised the 
estimation of the prototypes' strength when classifying a new 
instance not included in the original set. This strength was eval-
uated on the basis of different classifier performance tests. Due 
to the great difference between the number of genes (predictive 
variables) and the instances of each experiment, many distinct 
and equally effective classifiers may exist for the same training 
set [34]-[37]. This fact led us to consider four different clas-
sification models instead of only one. Furthermore, and trying 
to cover a wide range of classical paradigms, the four models 
chosen come from different classification families and are com-
monly used in DNA microarray class prediction studies [36]. 
1) Logistic Regression—Logistic regression [3 8] has become 
a very widely used classification paradigm in life sciences 
because its parameters can be interpreted as risk factors. 
Logistic regression is based on the logistic function and 
it allows an interpretation in probability terms. A set of 
parameters has to be estimated from the problem data, usu-
ally known as regression coefficients. Usually, regression 
coefficients are estimated using the maximum likelihood 
estimation method, but there are adaptations that penalize 
this maximum likelihood with other factors. The logistic 
regression model used in this paper penalizes the like-
lihood estimation with an estimator known as the ridge 
estimator [39]. 
2) k-Nearest Neighbor—The fc-NN algorithm [40] proceeds 
with the classification task in terms of similarity: unla-
beled examples are classified based on their distance to 
the examples in the training set. fc-NN is a classification 
paradigm with no explicit classification model. In other 
words, there is no learning stage at which a mathemati-
cal model is induced, and from which the categorization 
stage is tackled. It finds the fc closest features in the data 
and assigns them to the class that most frequently appears 
within the fc-subset. In this work, fc-NN is computed with 
Euclidean distance and a fc value of three. 
3) Naive Bayes—Continuous naive Bayes [41] belongs to 
the Bayesian classifier family. This family is based on 
the Bayes formulation of conditional dependencies [42]. 
Bayesian classifiers need to specify a structure, and then, 
a series oí a priori and conditional probabilities, or model 
parameters. The simplest structure is the naive Bayes 
structure based on the assumption of the conditional inde-
pendence between the predictor variables given the class. 
The model parameters are estimated with a factoriza-
tion based on the normal distribution assumption for each 
variable. 
4) Random Forest—This classification paradigm belongs to 
the tree-like classification family. Random forest [43] 
builds a forest composed of t random trees. When build-
ing these trees, a random variable selection is performed. 
The random tree set is learnt using a bootstrap instance 
selection, and the built trees are not pruned. For our paper, 
no variable selection is configured at the induction step, 
because a feature selection has already been performed. 
Thus, using all the predictive variables provided, ten ran-
dom trees are built for each forest. 
In order to obtain a fair estimation of each classifier per-
formance, a crucial task arose: the choice of the most suit-
able accuracy estimation method in the context of the microar-
rays. Classical methods such as hold-out, simple, or leaving-
one-out cross validations [44] have been demonstrated not to 
fit on the intrinsic microarray dimensionality problem [45], 
[46]. Nowadays, there are two main approaches commonly ac-
cepted as the best estimation techniques: the corrected boot-
strap estimator [47] and nested stratified cross validation 
[48]. 
For the present study, we chose the use of a nested strati-
fied cross-validation scheme as the accuracy estimation method. 
This method comprises the performance of two different stages: 
one internal (or inner) loop in which the parameters of the clas-
sification methods are estimated; and an external (or outer) loop 
in which the classifiers are induced and validated against previ-
ously unseen instances. In our specific case, the feature selection 
methods were run throughout the inner loop and the different 
classifiers were induced on the basis of these selected features. 
TABLE II 
ESTIMATED ACCURACIES OBTAINED FOR THE TEN TIMES FOLD 
CROSS-VALIDATION ON EACH CLASSIFICATION PARADIGM 
Set size 
Log. reg. 
Naive Bayes 
fc-NN 
Rand, forest 
r = n3Gi 
6.17Í0.72 
86.75i3.72 
86.75i5.01 
88.50i4.50 
80.25i8.98 
^Eq.Width 
25.57i3.19 
95.25i3.05 
97.00il.00 
100.0i0.00A 
95.75i2.75 
^Eq.Freq. 
38.83i2.01 
95.25i2.61 
96.25i2.02 
100.0i0.00A 
93.00i4.44 
^ Entropy 
41.42i3.02 
95.00i3.35 
96.75i2.25A 
98.75i2.02A 
90.25i4.39 
This classifier is tested over instances not previously seen on the 
induction stage. 
The next parameter to adjust was the number of times that 
all this process is done for each classifier and for each feature 
selection method. Taking advantage of previous studies, it is 
proven that the ten times repetition of ten of these stratified 
cross validations obtains suited accuracy estimations [46], [49]. 
This validation scheme is usually known as ten times tenfold 
cross validation. 
As for the study of the prototype's classification strength, we 
performed the validation over four different gene sets: the in-
termediate genes selected by the correlation feature selection 
over the three different discretized data sets, and the consensus 
prototype genes. The number of selected genes and estimated 
accuracies are gathered in Table II. All the induction and valida-
tion processes were computed using the WEKA framework [50]. 
To assess the significance and reliability of the consensus 
genes in comparison with each one of the intermediate gene sets, 
a corrected repeated k-fold cv test [49] was performed. This sta-
tistical test has been proven as one with the most suited relation 
between the type I and II errors [49], [51] and a high replica-
bility degree [49]. The test compares the differences between 
two different classification algorithms by a special corrected 
t-test. The null hypothesis is that both algorithms have the same 
classification behavior; the alternative hypothesis states that one 
algorithm outperforms the classification degree of the other. 
For each base classifier, the accuracy of each single dis-
cretization policy was compared with respect to the consensus 
approach. For all the 12 comparisons, only four of them (val-
ues with a Á symbol on Table II) rejected the null hypothesis 
for an a = 0.05 significance level. For a 0.01 level, none of 
them showed statistical differences—the null hypothesis was 
not rejected in any of them. These results let us state that, while 
suffering a decrease on the classification accuracies, the dif-
ferences between the use of the consensus prototypes and the 
intermediate selected gene sets are not statistically significant 
in many comparisons. 
B. Biological Analysis 
1) Verification of Microarray Hybridization by Quantita-
tive RT-PCR Analysis: For verification of hybridization sig-
nals, quantitative TaqMan PCR analysis was performed for five 
selected genes. Two of these genes (H1F0 and SP100) are IFN-
regulated genes previously associated with SLE [29], [30]. Our 
microarray data showed that both genes were upregulated in 
TABLE III 
qPCR OUTPUT VALUES AND EXPECTED ACTIVITY FOR FIVE GENES FROM 
THE RELEVANT GENELIST 
Symbol Phenotype Median lst-quartil 3rd-quartil Expected 
H1F0 
GNLY 
SSB 
p-value 
Control 
SLE 
PAPS 
Control 
SLE 
PAPS 
Control 
SLE 
PAPS 
Control 
SLE 
PAPS 
Control 
SLE 
PAPS 
0.0 
1.66 
2.08 
-0.32 
0.8 
-1.39 
0.0 
-0.1 
-2.65 
0.0 
0.8 
-3.17 
-0.16 
3.19 
-1.22 
-0.99 
1.0 
1.01 
-1.37 
0.4 
-1.99 
-1.34 
-0.79 
-3.26 
-1.51 
-0.28 
-3.56 
-1.09 
2.26 
-2.03 
0.99 
2.16 
3.14 
1.04 
1.56 
-0.7 
1.26 
0.58 
-1.93 
1.51 
1.66 
-1.41 
0.97 
3.33 
-0.89 
-
UP 
UP 
-
BASELINE 
DOWN 
-
BASELINE 
DOWN 
-
BASELINE 
DOWN 
-
UP 
DOWN 
-
< 0.0001 
0.00264 
-
0.12506 
0.06598 
-
0.95635 
< 0.0001 
-
0.20110 
< 0.0001 
-
0.00076 
0.07220 
Biological process* Level: 3 
cellular netabolic process 
prinary netabolic process 
nacronolecule netabolic process 
regulation of biological process 
cell organization and biogenesis 
establishnent of localization 
cell connunication 
anatonical structure developnent 
nulticellular organisnal developnent 
cellular developnental process 
protein localization 
biosynthetic process 
death 
response to stress 
innune systen process 
defense response 
response to biotic stinulus 
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Fig. 3. qPCR validation summary for five genes from the relevant genelist. 
SLE patients, but only H1F0 expression was increased in PAPS, 
whereas SP100 expression was downregulated. 
SSB, also called La autoantigen, is a ribonucleoprotein in-
volved in chromatin metabolism, and is known to elicit autoan-
tibody responses in SLE [28]. Its expression in SLE samples 
was similar to controls, but was downregulated in PAPS. The 
remaining two genes (GNLY and PPIA) that were selected for 
PCR analysis are known to have a role in the execution of im-
mune functions [52]-[54] and were found to be downregulated 
in PAPS samples. 
In order to perform a rigorous validation, we used a sec-
ond cohort of SLE and PAPS samples, a total of 14 new blood 
samples not used in the microarray analyses. The qPCR sam-
ple distribution was as follows: six healthy controls, three SLE 
samples, and five PAPS samples. Detailed information of each 
sample is gathered online. 
For each gene and phenotype, DDiff values were calculated 
(see Section II), and the median values of these DDiff, to-
gether with the expected gene expression activities are shown in 
Table III. As a dispersion measure of the results, the values 
for the first and third quartile of each group of values are also 
shown. Fig. 3 graphically summarizes the results obtained for 
each gene within the qPCR validation. 
Fig. 4. Gene ontology biological process (level 3) annotations that are signif-
icantly overrepresented in the list of dysregulated genes. Annotations with an 
incidence level lower than 5% are not shown. 
As a criterion, a median DDiff value between — 1 and 1 was 
considered a baseline activity, that is, unchanged with respect to 
healthy controls. Median values higher than 1 reflect an upreg-
ulated activity, while values lower than — 1 reflect a downreg-
ulated activity. Clearly, the expected gene expression profiling 
as measured by microarray quantitation is fully validated by the 
qPCR experiment. 
As a final validation criterion for the expected gene expres-
sion activities, a statistical test was performed comparing the 
DDiff expression values between the control samples and either 
SLE or PAPS samples. Column p-value in Table III gathers the 
output of a nonparametric Mann-Whitney hypothesis test [55], 
showing that all the values of over or underexpression are statis-
tically significant for a 90%; confidence level. In addition, the 
p-values for the baseline activities show no statistically signifi-
cant differences between these cases and the control expression. 
Thus, all these results are consistent with the expected expres-
sion activity for each gene. 
2) Functional Characterization of the Relevant Genes in SLE 
and PAPS: To check whether the results made sense from a bi-
ological point of view, we have analyzed the list of dysregulated 
genes with the FatiGO+ tool [56]. FatiGO+ can be used to 
search for the GO annotations2 that are overrepresented in a list 
of genes. The significance of the overrepresentation is assessed 
by means of a Fisher exact test. From the 150 dysregulated 
genes identified, only 112 have GO annotations. Fig. 4 shows 
the results obtained with this tool (for terms in the level 3 of 
GO biological process annotations). As we can see in the figure, 
immune-system-related annotations, such as defense response 
or immune system process, are overrepresented in the list of 
dysregulated genes. 
A comparison with previous studies on microarray analyses 
revealed a notable similarity in the functional categories of the 
genes found to be dysregulated in our analysis [57], confirming 
their importance in the pathogenesis of the disease IV. Such 
2
 Gene Ontology Consortium http://www.geneontology.org 
TABLE IV 
SOME OF THE GO FUNCTIONAL GROUPS IDENTIFIED FROM THE RELEVANT 
GENELIST AND THE GENES THAT BELONG TO EACH GROUP 
TABLE V 
LOCATION OF THE DETECTED REGULATOR GENES 
Functional group Genes 
Cellular metabolic process 
Primary metabolic process 
Macromolecule metabolic process 
Regulation of biological process 
Cell organization and biogenesis 
Establishment of localization 
Cell communication 
Defense response 
Immune system processes 
Response to chemical stimulus 
Death 
GAS7, DDX5, RRAGD, MBD4, 
CECR1, CUTL1, PTMA 
SNRPD2, CPSF1, SSB, SFRS2IP, 
PPIG, NADK, DNPEP, HSD17B4, 
NAGPA, ZNF202, ABCA1, 
COMT 
EIF4A1, EIF3S8, RPL18A, 
MRPL9, HSF2, HSPA6, PFDN4, 
HSPA8, HSP90B1 
KRAS, TMEM97, GPS1, UQCRB, 
CYB561, TNKS2, ZNF83, 
ZNF587, POLR2K, GMEB2, 
SP100 
HIST1H1C, TSPYL4, H1F0 
RIN3, SLC25A12, UQCRB, 
CYB561, SYPL1, GOSR1, 
KDELR2, C14orfl08, GOLGA4, 
KPNB1, SLC25A5, PEX1 
GNB2L1, CDC42EP3, IQGAP1, 
PKN1, RAB2, TAX1BP3, ARF3, 
ANK3 
WAS, TAP1, GNLY, NMI, CD 160 
ISG15, IGHM, HLA-DQB1, 
GPSM3, MX1 
HSPA6, HSPA8 
BAG5, TNFRSF10B, CASP1, 
SIRT1 
is the case of the categories defense response, immune system 
process, death, cell communication, or response to chemical 
stimulus. In addition, our analysis revealed other relevant func-
tions, including metabolism, establishment of localization, or 
regulation of biological processes that have not been previously 
associated with SLE or PAPS, and that may provide important 
clues about the pathogenesis of these diseases. 
3) Regulatory Pathways Dysregulated in SLE and PAPS: It 
is believed that mutations in susceptibility genes that contribute 
to the pathogenesis of a given disease result in an altered expres-
sion and/or activity of genes regulated by them, thus revealing 
a particular molecular signature of the disease [58]. Taking this 
idea into account, we searched for factors that could be regulat-
ing the genes whose expression is altered in SLE and/or PAPS. 
For each of the 150 genes identified in the original set, and using 
the ingenuity pathways analysis tool,3 the factors that could be 
involved in the regulation of their expression or activity were 
identified. Only those genes with known regulators were consid-
ered for subsequent analyses. Furthermore, genes regulated by 
other genes included in the original set were discarded because 
it is not possible to know whether these genes are dysregulated 
due to a mutation in the genes that regulate their expression or 
because their regulators are dysregulated themselves. 
The resulting filtered set includes a total of 129 genes (out 
of 150), and the gene set known to regulate them contains a 
total of 299 genes. Only the genes regulating three or more 
For a detailed description of ingenuity pathways analysis, visit: 
http://www.ingenuity.com 
Regulator 
IL15 
IFNG 
MYC 
TP53 
EGF 
HGF 
TNF 
PTEN 
TGFB1 
IFNA1 
IFNA2 
CDC42 
BCL2 
FOS 
TNFSF10 
MYCN 
SRC 
Regulated genes 
BTG1, GNLY, PFDN4, POLR2K, 
SELPLG, SLC25A5, SP100 
ABCA1, CYB561, HSPA8, MX1, 
PSMB4, TNFRSF10B 
ARF3, DDX5, PPIA, SLC25A5, 
TNFRSF10B 
COMT, DLG1, ISG15, THRAP2, 
TNFRSF10B 
GNB2L1, HK1, MVP, WAS 
ANK3, ISG15, HK1, TMEM97 
ANXA2, BTG1, ISG15, MVP 
BTG1, CYB561, ISG15, RPL36A 
ANXA2, KDELR2, KPNB1, 
TAX1BP3 
CYB561, ISG15, MX1, NMI 
MX1, SP100, TNFRSF10B 
IQGAP1, PKN1, WAS 
CASP1, IGHG1, KRAS 
CPSF1, SNRPD2, HSP90B1 
ISG15, SP100 , TNFRSF10B 
EIF4A1, RPL37A, RPS25 
ACPI , ANXA2 , GNB2L1 
Locus 
4q31 
12ql4 
8q24.12-
13 
17pl3.1 
4q25 
7q21.1 
6p31.3 
10q23.31 
19ql3.1 
9p22 
9p22 
lp36.1 
18q21.3 
14q24.3 
3q26 
2q24.1 
20ql2-
13 
Ref. 
[59], 
[59], 
[61] 
[60] 
[60] 
[63]-[65] 
[59], 
[60], 
[59], 
[59] 
[60], 
[60] 
[62] 
[62] 
[61] 
target genes were considered, which resulted in a final num-
ber of 17 regulatory genes controlling the expression of a total 
of 45 dysregulated genes (see Table V). Finally, their loca-
tion within the genome was sought. Remarkably, nearly half of 
them (8 out of 17) were found to be located in chromosome 
regions previously reported as susceptibility regions for SLE 
[59H66]. 
Recent microarray reports have suggested that the interferon 
regulatory pathway could be an important contributor of SLE, 
based on the dysregulated expression of numerous interferon-
inducible genes in lupus samples [67]-[69]. Remarkably, our 
analyses revealed that three of the regulatory genes are interferon 
proteins (IFNG, IFNA1 and IFNA2), regulating the expression 
and/or activity of nine genes identified in the microarray experi-
ments. Seven of these nine genes were overexpressed in SLE pa-
tients, consistent with previous findings. Moreover, three more 
regulator proteins (IL15, MYC, TNFSF10) are also known to 
be regulated by IFNs. These results indicate that the IFN path-
way regulates nearly half of the regulatory genes identified in 
our analysis, either directly or indirectly, corroborating the im-
portance of the interferon signature in SLE, and suggesting an 
important role for this pathway also in PAPS pathogenesis. 
Other regulatory genes with a known or suspected role in 
autoimmunity were also present in the search. Such is the case 
of PTEN, a phosphatase involved in the regulation of the PI3K 
pathway [70], TNF, tumor necrosis factor [71], or the antiapop-
totic protein Bcl-2 [72]. It will be worth examining these regu-
latory networks in more detail, to determine their contribution 
to the pathogenesis SLE or PAPS, as well as their usefulness as 
markers of these diseases. 
4) Analysis of Transcription Factor Binding Sites in the Pro-
moters of Genes Relevant for SLE and PAPS Identification: 
TABLE VI 
DEREGULATED TRANSCRIPTION FACTORS FOUND IN BASIS OF THE IDENTIFIED RELEVANT GENE SET 
Frequency 
z-value 
sample mean 
population mean 
ratio 
p-value 
Incidence 
number 
sample mean 
population mean 
ratio 
p-value 
IRF2 
2.81 
0.061 
0.021 
2.9 
0.0049 
5 
4.35% 
2.02% 
2.2 
0.0840 
IRF1 
2.05 
0.078 
0.039 
2.0 
0.0408 
7 
6.09% 
3.79% 
1.6 
0.1474 
PAX2 
2.71 
0.026 
0.006 
4.2 
0.0067 
3 
2.61% 
0.62% 
4.2 
0.0355 
SP1 
2.23 
2.278 
1.824 
1.2 
0.0256 
78 
67.83% 
68.09% 
1.0 
0.4043 
Genes that participate in a particular pathway often share a 
common transcription factor binding site. We next explored the 
possibility that the dysregulated genes in SLE and PAPS could 
be regulated by common transcription factors involved in the 
development of autoimmunity. We reasoned that if a significant 
number of dysregulated genes in SLE and PAPS were regu-
lated by a common transcriptional factor, then this factor could 
somehow be associated with the disease. 
We made use of the transcription element listening sys-
tem [73], also known as TELiS, to identify transcription factor-
binding motifs (TFBM) that are overrepresented in the promot-
ers of a given gene set. This analysis considers two variables 
for any binding motif: 1) the frequency of this motif per gene: a 
comparison is made between the average frequency within the 
whole microarray and the frequency in the genes of the relevant 
list; 2) the number of genes exhibiting this motif in the relevant 
list compared to the whole microarray. Using these values, it 
is possible to compute a z-value statistic [74] and to perform a 
two-tailed hypothesis test based on a Bernouilli-set trial that ex-
amine these TFBMs that are overrepresented in the test list with 
respect to the expected occurrence computed from the original 
microarray list. 
In our case, the parameters for the genome scan were as fol-
lows: the promoter search interval was fixed between —1000 
and +200 bp, and the stringency of the test is fixed to a 
0.9 value. TELiS analysis identified a total of 115 genes 
from the total of 141 mapped genes in the relevant gene set. 
Within these parameters, TELiS reported a total number of 
seven overrepresented transcription factor binding motifs (see 
Table VI). Importantly, two interferon response elements (IRF1 
and IRF2) appeared as overrepresented, again revealing the im-
portance of the IFN-regulated pathway in these autoimmune 
diseases. The binding sites for SP1 and P300 were also sig-
nificantly overrepresented, particularly with regard to the fre-
quency of binding sites per gene. However, the increase in 
frequency as well as in incidence were minimal with respect 
to the reference control, and it is unlikely to be biologically 
meaningful. 
PAX2 and MEF2 are transcription factors that are known to be 
involved in cellular differentiation and organ development [75]. 
The finding that their binding sites are overrepresented in our 
analysis suggests that factors regulating differentiation also play 
a role in autoimmunity. Remarkably, E2F binding sites were 
MEF2 
2.15 
0.035 
0.013 
2.8 
0.0318 
P300 
2.14 
2.148 
1.857 
1.2 
0.0323 
E2F 
2.10 
0.157 
0.095 
1.7 
0.0353 
CDXA 
-2.33 
2.470 
3.234 
0.8 
0.0200 
CREBP1CJUN 
-2.08 
0.009 
0.055 
0.2 
0.0377 
4 105 17 81 1 
3.48% 91.30% 14.78% 70.43% 0.87% 
1.25% 82.54% 8.86% 79.47% 5.28% 
2.8 1.1 1.7 0.9 0.2 
0.0572 0.0060 0.0251 0.0059 0.0132 
found overrepresented in this analysis. E2F constitutes a family 
of transcription factors involved in the transcriptional regulation 
of genes necessary for cell cycle control [76]. Recently, func-
tional inactivation of E2F2, a member of this family, has been 
found to promote a lupus-like autoimmune disease in a mouse 
model, linking cell cycle regulation to autoimmunity [77]. Ad-
ditionally, reduced expression of E2F2 has been reported in SLE 
patients [68]. These findings project a role for E2F in the reg-
ulation of autoimmunity, and suggest that modulation of E2F 
levels could be beneficial in these diseases. 
IV. CONCLUSION 
Consensus approaches are alternative techniques that try to 
overcome the technology-intrinsic data noise in microarray 
experiments. In the present paper, we applied a supervised 
consensus gene selection method, aiming to add robustness 
to the biomarker identification procedures by means of DNA 
microarray s. 
Microarray studies must deal with "the curse of dimension-
ality" and "the curse of sparsity" [78]: in a problem with a huge 
number of variables (features or genes), there are only a small 
number of instances (cases or samples) whereas there are sev-
eral thousand variables. Therefore, their results must be strictly 
proven to assess reliability over the given statements. Through-
out this paper, in-depth statistical and biological validations have 
been successfully carried out. 
Readers should note the importance of being conservative 
when dealing with findings coming from a low number of sam-
ples. Within some rare diseases, such as SLE and PAPS, it is 
very difficult for physicians and clinics to find samples cohorts. 
Therefore, studies in these fields must be able to deal with these 
adversities while they bring some light into the present genomic 
research. Throughout this paper, from the starting feature selec-
tion to the final biological validations, we have exposed a battery 
of techniques, both from statistics and biology, to add reliability 
and proofs to the results of such researches. Authors consider 
of special importance the posterior validation of the findings 
by means of qPCR analysis with outer samples not used in the 
previous statistical stages. 
Among these findings, the statistical techniques applied have 
corroborated the importance of the IFN pathway in SLE and 
PAPS, and have also revealed the existence of other gene 
signatures that could be playing an important role in the patho-
genesis of these diseases. Future clinical and/or biological tests 
over the presented results could throw light on the molecular 
basis of SLE and PAPS diseases. 
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